[go: up one dir, main page]

BRPI0507958A - biomarcadores - Google Patents

biomarcadores

Info

Publication number
BRPI0507958A
BRPI0507958A BRPI0507958-6A BRPI0507958A BRPI0507958A BR PI0507958 A BRPI0507958 A BR PI0507958A BR PI0507958 A BRPI0507958 A BR PI0507958A BR PI0507958 A BRPI0507958 A BR PI0507958A
Authority
BR
Brazil
Prior art keywords
biomarkers
cytotoxic agent
cancer
sensitivity
determining
Prior art date
Application number
BRPI0507958-6A
Other languages
English (en)
Inventor
Iwan Beuvink
Anne Boulay
Heidi Lane
Terence O'reilly
George Thomas
Original Assignee
Novartis Ag
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Forschungsstiftung filed Critical Novartis Ag
Publication of BRPI0507958A publication Critical patent/BRPI0507958A/pt

Links

Classifications

    • G01N33/57575—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"BIOMARCADORES". A presente invenção refere-se a biomarcadores para determinar a sensibilidade de doenças proliferativas tal como câncer a agentes terapêuticos, em particular inibidores de mTOR em combinação com um agente citotóxico, em particular um agente citotóxico que danifica a integridade do DNA.
BRPI0507958-6A 2004-02-23 2005-02-22 biomarcadores BRPI0507958A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54685604P 2004-02-23 2004-02-23
PCT/EP2005/001849 WO2005080593A2 (en) 2004-02-23 2005-02-22 P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent

Publications (1)

Publication Number Publication Date
BRPI0507958A true BRPI0507958A (pt) 2007-07-17

Family

ID=34886278

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507958-6A BRPI0507958A (pt) 2004-02-23 2005-02-22 biomarcadores

Country Status (12)

Country Link
US (1) US7749698B2 (pt)
EP (2) EP1721007A2 (pt)
JP (1) JP5005355B2 (pt)
KR (2) KR20120084333A (pt)
CN (1) CN1957092B (pt)
AU (1) AU2005215910B2 (pt)
BR (1) BRPI0507958A (pt)
CA (1) CA2555542A1 (pt)
ES (1) ES2494915T3 (pt)
MX (1) MXPA06009550A (pt)
RU (2) RU2429297C2 (pt)
WO (1) WO2005080593A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO346575B1 (no) * 2005-11-21 2022-10-17 Novartis Ag Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av carcinoid eller småøyet celle cancer
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
RU2447891C2 (ru) * 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
DK2245464T3 (en) * 2008-01-25 2017-02-20 Multivir Inc P53 BIOMARKETS
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
GB2488028A (en) * 2011-02-09 2012-08-15 Astrazeneca Ab mTOR mutants as biomarkers for mTOR inhibitor treatment
BR112013029704A2 (pt) * 2011-05-19 2017-08-29 Toray Industries Agente de indutor de imunidade e uso de um agente indutor de imunidade
RU2509808C1 (ru) * 2012-10-30 2014-03-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53
JP6055430B2 (ja) * 2013-03-29 2016-12-27 三ツ星ベルト株式会社 伝動用ベルト
RU2558860C1 (ru) * 2014-03-28 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) Способ прогнозирования лимфогенного метастазирования при трипл негативной инвазивной карциноме неспецифического типа молочной железы
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112023001575A2 (pt) * 2020-07-30 2023-04-04 Diadem S P A Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo
CN117942400A (zh) * 2022-10-31 2024-04-30 四川大学 Beclin 1抑制剂在制备治疗p53野生型癌症的药物中的用途
CN117942399A (zh) * 2022-10-31 2024-04-30 四川大学 USP5抑制剂在制备治疗p53野生型癌症的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
DK0863984T3 (da) * 1995-11-30 2006-08-28 Univ Texas Fremgangsmåder og præparater til behandling af cancer
DE69907151D1 (de) * 1998-02-18 2003-05-28 Theryte Ltd Krebsbehandlung
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane

Also Published As

Publication number Publication date
WO2005080593A8 (en) 2006-10-19
EP2228452A1 (en) 2010-09-15
EP1721007A2 (en) 2006-11-15
KR20070022665A (ko) 2007-02-27
RU2385944C2 (ru) 2010-04-10
JP5005355B2 (ja) 2012-08-22
US7749698B2 (en) 2010-07-06
JP2007522812A (ja) 2007-08-16
US20080194613A1 (en) 2008-08-14
RU2008116567A (ru) 2009-11-10
AU2005215910A1 (en) 2005-09-01
MXPA06009550A (es) 2007-03-01
EP2228452B1 (en) 2014-07-16
WO2005080593A2 (en) 2005-09-01
KR101382077B1 (ko) 2014-04-10
ES2494915T3 (es) 2014-09-16
RU2006133828A (ru) 2008-03-27
AU2005215910B2 (en) 2008-05-01
KR20120084333A (ko) 2012-07-27
CN1957092B (zh) 2013-04-03
WO2005080593A3 (en) 2005-11-24
CN1957092A (zh) 2007-05-02
CA2555542A1 (en) 2005-09-01
RU2429297C2 (ru) 2011-09-20

Similar Documents

Publication Publication Date Title
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
BRPI0507958A (pt) biomarcadores
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
TW200738263A (en) ANG2 and VEGF inhibitor combinations
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
MX2007014132A (es) Compuestos de diarilhidantoina.
MX353964B (es) Agentes terapeuticos y usos de los mismos.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
BR112013008140A2 (pt) "compostos imidazotriazinona".
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
EP1967209A4 (en) THERAPEUTIC AGENT AGAINST PROSTATE CANCER
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
TW200744568A (en) Epinephrine dosing regimens
MX2015005448A (es) Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL